Month: June 2023

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) — Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) is pleased to announce that the Company has filed the Management Information Circular (“Circular”) in connection with the annual, general and special meeting of Lithium Americas shareholders to be held on July 31, 2023 (the “Meeting”). The Meeting will be held to consider the approval of the reorganization of the Company that will result in the separation of its North American and Argentine business units into two independent public companies (the “Separation”) and annual meeting matters, among other things. The Separation will establish the Company as Lithium Americas (Argentina) Corp. (“Lithium Argentina”), as well as a new company to be named Lithium Americas Corp. (“Lithium Americas...

ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the on-demand treatment of HAE following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study. Pharvaris expects to submit data from the 26-week nonclinical study by the end of 2023 to address the remaining hold on the IND application for deucrictibant for prophylactic treatment of HAE. “The lift of the clinical hold on our on-demand clinical trials enables us to continue development of PHVS416 (deucrictibant immediate-release...

Castellum, Inc. Formally Joins Russell Microcap Index; Comments on Recent Stock Trading Volume Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity and electronic warfare services company focused on the federal government, is pleased to announce that it has officially joined the Russell Microcap Index, effective as of the end of trading on June 23, 2023 – https://castellumus.com/BETHESDA, Md., June 26, 2023 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity and electronic warfare services company focused on the federal government, is pleased to announce that it has officially joined the Russell Microcap Index, effective as of the end of trading on June 23, 2023. “Joining the Russell Microcap Index is a key milestone for Castellum,” said Mark Fuller, President, and...

CUPERTINO, Calif., June 26, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that the Company will be added to the Russell Microcap® Index, effective after the United States market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and...

An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model,” which were presented during the American Diabetes Association (ADA) 83rd Scientific Sessions, held June 23–26, 2023 in San Diego, California. “In this preclinical study, we assessed the bioavailability of semaglutide when delivered via our BioJet device in a porcine model. Following administration of semaglutide, the average oral bioavailability was 37%,...

TORONTO, June 26, 2023 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or “the Company”) (TSX: FM) will release second quarter 2023 financial and operating results on Tuesday, July 25, 2023 after the close of the Toronto Stock Exchange. The Company will host a conference call and webcast to discuss the results on Wednesday, July 26, 2023 at 9:00 am (ET). Conference call and webcast details:Toll-free North America: 1-800-319-4610Toll-free International: +1-604-638-5340Webcast: Direct link or on our website A replay of the webcast will be available on the First Quantum website. For further information, visit our website at www.first-quantum.com or contact: Bonita To, Director, Investor Relations (416) 361-6400 Toll-free: 1 (888) 688-6577E-Mail: info@fqml.com  

PITTSBURGH and TEL AVIV, Israel, June 26, 2023 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a leader in semiconductor lasers, and TriEye Ltd., a pioneer in mass-market shortwave infrared (SWIR) sensing technology, today announced their successful joint demonstration of a laser-illuminated SWIR imaging system for automotive and robotic applications. The growing number of use cases for SWIR imaging, which expands vision in automotive and robotics beyond the visible spectrum, is driving demand for low-cost mass-market SWIR cameras. The companies leveraged TriEye’s spectrum enhanced detection and ranging (SEDAR) product platform and Coherent’s SWIR semiconductor laser to jointly design a laser-illuminated SWIR imaging system, the first of its kind that is able to reach lower cost points while achieving very high performance over...

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) — Inflection Resources’ (CSE:AUCU) (OTC:AUCUF) (FSE:5VJ) President and CEO, Alistair Waddell, discusses Definitive Farm-in Agreement with AngloGold Ashanti Australia Limited that outlines the terms under which AngloGold may earn into a number of Inflection’s copper-gold projects in New South Wales, Australia, in interview with David Morgan of the Morgan Report. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “Inflection” in the search...

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) — Reflex Advanced Materials Corp. (CSE: RFLX), (OTCQB:RFLXF), (FSE:HF2) (“Reflex” or the “Company”), announces that it has engaged Childs Geoscience Inc. (CGI) for managing its initial drill program (the “Program”) at the Ruby Graphite Deposit. Expected to kick-off in late June 2023, the Program will consist of at least 3,500 meters of diamond core drilling at the Project, located in Beaverhead County, Montana, U.S.A. CGI will also carry forward with other geological studies on the Project, such as geophysical surveys, outcrop inspection and sampling, and preparing technical reports. Due to its history of commercial graphite production, the Project is prospective for natural crystalline graphite. As the Project will be fully permitted until 2024 for more than 20 different...

Study Intends To Identify Hematology Biomarkers That May Help Personalize Medical Evaluations For Patients Undergoing Treatments For Macular Degeneration PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the management of ocular injections, which have become a significant healthcare burden due to their associated complications in treating macular degeneration-related vision loss. “We are near completion of an IRB for research on its DNA/GPS program. We intend to conduct the study on 100 patients in an effort to establish standards for determining effective and ineffective eye...